# Cathepsin Activatable Fluorescent Probe

> **NCT01626066** · PHASE1 · COMPLETED · sponsor: **David Kirsch** · enrollment: 15 (actual)

## Conditions studied

- Sarcoma
- Soft Tissue Sarcoma
- Breast Cancer

## Interventions

- **DRUG:** LUM015

## Key facts

- **NCT ID:** NCT01626066
- **Lead sponsor:** David Kirsch
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2014-08
- **Final completion:** 2015-08
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2015-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01626066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01626066, "Cathepsin Activatable Fluorescent Probe". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT01626066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*